Lilly in $440M osteoporosis patch deal with Zosano
Eli Lilly and Co. said Tuesday it will team up with Zosano Pharma Corp. on an experimental osteoporosis patch in a deal that could be worth more than $440 million.
Eli Lilly and Co.
Articles
Fifth person pleads guilty in Lilly warehouse heist
Prosecutors say the theft from an Eli Lilly and Co. warehouse in Connecticut involved up to $100 million in prescription drugs.
New type of cholesterol drug shows promise in study
The results have immediate implications for 1 million Americans who suffer mild heart attacks or chest pain each year. They may also make it easier for other experimental medicines from companies such as Eli Lilly to reach patients.
Top 4 questions for Hoosier health care after GOP takes control of Congress
On Obamacare, the new Republican-controlled Congress should “leave the façade of the building and then demolish the inside of it,” according to one GOP leader. If Republicans take that approach, here are four things that could change in the next two years.
Two plead guilty in $50M Lilly prescription drug theft
Prosecutors said the two men and three others broke into a Lilly warehouse in March 2010 and stole thousands of boxes of drugs, including Zyprexa, Cymbalta, Prozac and Gemzar.
Research firm Covance to be acquired in $6.1 billion deal
Covance manages clinical trials for drugmakers including locally-based Eli Lilly and Co. It employs about 1,500 workers in Indianapolis and Greenfield.
Alzheimer’s drug makes Avanir potential Lilly target
Eli Lilly and Co. would be a logical acquirer for the maker of a drug that could treat agitation in Alzheimer’s patients.
Eli Lilly donates $12.7 million to United Way
The donation represents the giving of employees and retirees of Lilly and Elanco Animal Health in the U.S. and Puerto Rico, plus a matching contribution from the Lilly Foundation.
Takeda, Lilly win 99-percent cut in Actos damages award
Judge Rebecca Doherty in Lafayette, Louisiana, said the jury’s decision to order Takeda to pay $6 billion and Lilly $3 billion was excessive and should be reduced to a total of $36.8 million.
Lechleiter: It’s morning at Eli Lilly
Lilly CEO John Lechleiter kicked off the company’s quarterly conference call with investors and analysts by declaring an end to the “unprecedented challenge” that Lilly lived through the past four years.
Lilly adds $375M to Zymeworks partnership
Eli Lilly and Co. and Zymeworks said Wednesday that they are expanding a cancer drug development partnership.
Lilly third-quarter earnings fall below Wall Street’s expectations
The Indianapolis drugmaker's profit tumbled 58 percent as cheaper generic medicines took sales from blockbusters Cymbalta and Evista.
Eli Lilly to sell Puerto Rico manufacturing facility
The Indianapolis company said it is closing its Guayama facility because the patents on some of the drugs made there have expired.
Lilly partner ordered to pay more than $2M to ex-Actos user
Takeda Pharmaceutical Co. was ordered by a jury to pay more than $2 million to a woman who claimed the company’s Actos diabetes medicine caused her bladder cancer, in the latest of thousands of lawsuits involving the drug to go to trial.
Lilly partner accused of putting Actos profit ahead of safety
Executives knew by 2004 that studies found links between Actos and cancer, and didn’t issue a warning until seven years later to protect billions of dollars in sales of the drug, attorney Michael Miller told a state-court jury in Philadelphia on Thursday.
European regulators OK Lilly’s $5.4B Novartis deal
The European Union's antitrust authority has approved the $5.4 billion sale of Novartis' animal health division to Indianapolis-based pharmaceutical firm Eli Lilly and Co.
Lilly to end development of lupus drug after trial failure
Tabalumab was expected to generate about $250 million to $300 million a year in sales in several years.
Testosterone drugs need study on heart risks, FDA panel says
Drugmakers, including Eli Lilly and Co., should conduct new trials to assess the heart risks of testosterone therapies used by millions of men last year, advisers to U.S. regulators said.
FDA set to review testosterone-boosting drug usage
Testosterone supplements used last year by about 2.3 million men are spurring debates over how necessary and safe they may be, even as U.S. regulators consider approving a new product.
Lilly to pay AstraZeneca up to $500M in Alzheimer’s push
The two companies will work together to develop AZD3293, which belongs to a novel class of drugs called BACE inhibitors that block production of amyloid, a protein that causes plaque to build up in the brain of Alzheimer’s patients.